Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Actuarial Approach

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Active-Learning Resuscitation Leadership Curriculum for Emergency Medicine Residents.

MedEdPORTAL : the journal of teaching and learning resources·2026

Same author

The Crisis Stabilization Unit.

Child and adolescent psychiatric clinics of North America·2026

Same author

Closed Incision Negative Pressure Therapy for the Recipient Site in Head and Neck Reconstruction.

OTO open·2026

Same author

ECG-Based Deep Learning Estimation of VO2 Prognosticates Outcomes in Colorectal Surgery.

European journal of preventive cardiology·2026

Same author

Clinicopathological features and cancer-specific survival in young patients with ulcerative colitis-associated colorectal neoplasia: a nationwide cohort study in Japan.

Inflammatory bowel diseases·2026

Same author

Low Skeletal Muscle Mass as a Key Predictor of Postoperative Diet Outcomes in Circumferential Hypopharyngeal Cancer Reconstruction.

Laryngoscope investigative otolaryngology·2026

Search research articles

Related Experiment Video

Updated: Sep 11, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE Study.

Kohei Shigeta¹, Shodai Mizuno¹, Doruk Orgun²

¹Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Annals of Surgery

|August 13, 2025

Summary

This summary is machine-generated.

Recurrence Prediction Value (RPV) effectively identifies Stage II colon cancer patients who benefit from adjuvant chemotherapy (AC). This global validation aids in personalized treatment decisions for improved recurrence-free survival.

Keywords:

colon cancer high-risk factor recurrence prediction stratification

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Sep 11, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Oncology
Clinical Research
Cancer Prognostics

Background:

Adjuvant chemotherapy (AC) benefits in Stage II colon cancer are not fully established.
Accurate patient stratification is crucial for optimizing AC efficacy.

Purpose of the Study:

To validate the Recurrence Prediction Value (RPV) algorithm.
To identify Stage II colon cancer patients who benefit from AC.

Main Methods:

Multi-institutional international retrospective analysis of Stage II colon cancer patients.
RPV developed based on high-risk factors.
Validation using Japanese, US, Jordanian (Cohort 1), and Danish (Cohort 2) datasets.
Primary endpoint: recurrence-free survival (RFS).

Main Results:

RPV categorized patients into low-risk (approx. 70%) and high-risk (approx. 30%) groups across cohorts.
In the RPV high-risk group, AC significantly improved 5-year RFS (Cohort 1: 76.2% vs. 55.6%; Cohort 2: 65.6% vs. 49.8%).
Multivariate analysis confirmed AC as an independent prognostic factor for RFS in the RPV high-risk group (P<0.05 for both cohorts).

Conclusions:

The RPV algorithm is validated globally for predicting recurrence in Stage II colon cancer.
RPV identifies diverse patient populations who significantly benefit from adjuvant chemotherapy.
This tool supports personalized treatment strategies for Stage II colon cancer.